Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Accumulated Expenses (2017 - 2025)

Historic Accumulated Expenses for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to $52.3 million.

  • Autolus Therapeutics' Accumulated Expenses rose 1005.73% to $52.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.3 million, marking a year-over-year increase of 1005.73%. This contributed to the annual value of $52.3 million for FY2024, which is 3207.35% up from last year.
  • Per Autolus Therapeutics' latest filing, its Accumulated Expenses stood at $52.3 million for Q3 2025, which was up 1005.73% from $51.4 million recorded in Q2 2025.
  • Over the past 5 years, Autolus Therapeutics' Accumulated Expenses peaked at $52.3 million during Q4 2024, and registered a low of $23.7 million during Q4 2021.
  • Moreover, its 5-year median value for Accumulated Expenses was $36.7 million (2024), whereas its average is $38.6 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first plummeted by 1480.87% in 2021, then skyrocketed by 7237.93% in 2022.
  • Over the past 5 years, Autolus Therapeutics' Accumulated Expenses (Quarter) stood at $23.7 million in 2021, then surged by 72.38% to $40.8 million in 2022, then dropped by 2.98% to $39.6 million in 2023, then soared by 32.07% to $52.3 million in 2024, then decreased by 0.02% to $52.3 million in 2025.
  • Its Accumulated Expenses was $52.3 million in Q3 2025, compared to $51.4 million in Q2 2025 and $49.7 million in Q1 2025.